Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.47 Analyst target: $4.75 Upside: 223.13%
Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy, with a transformative approach to cancer treatment. Leveraging its pioneering induced pluripotent stem cell (iPSC) technology, Century is committed to developing innovative off-the-shelf therapeutics designed to improve patient outcomes and expand accessibility to care. With a diverse array of clinical-stage assets and strategic collaborations that enhance its market position, Century Therapeutics presents compelling investment opportunities in the burgeoning cell therapy landscape, positioning itself for significant growth within the biotech industry.
See the full interactive analysis & chart →Informational only — not investment advice.